Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease

被引：0
|
作者：
Kim, Wontak [1 ]
Maughan, Kyle S. [1 ]
Soh, Katherine K. [1 ]
Bearss, Jeremiah J. [1 ]
Bahr, Brigham L. [1 ]
Bearss, David J. [1 ]
Warner, Steven L. [1 ]
机构：
[1] Tolero Pharmaceut Inc, Lehi, UT USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting cancer-induced anemia with hepcidin lowering ALK2 inhibitors
    Peterson, Peter W.
    CANCER RESEARCH, 2015, 75
  • [2] ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease
    Peterson, Peter
    Soh, Katherine K.
    Lee, Ye Sol
    Kim, Wontak
    Whatcott, Clifford J.
    Siddiqui-Jain, Adam
    Bearss, David J.
    Warner, Steven L.
    BLOOD, 2015, 126 (23)
  • [3] TP-0184 IS AN INHIBITOR OF ALK2 AND A POTENTIAL THERAPEUTIC FOR THE TREATMENT OF ANEMIA OF CHRONIC DISEASE
    Peterson, Peter
    Kim, Wontak
    Haws, Hillary
    Whatcott, Clifford
    Siddiqui-Jain, Adam
    Bearss, David
    Warner, Steven
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (08) : E355 - E355
  • [4] Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
    Asshoff, Malte
    Petzer, Verena
    Warr, Matthew R.
    Haschka, David
    Tymoszuk, Piotr
    Demetz, Egon
    Seifert, Markus
    Posch, Wilfried
    Nairz, Manfred
    Maciejewski, Pat
    Fowles, Peter
    Burns, Christopher J.
    Smith, Gregg
    Wagner, Kay-Uwe
    Weiss, Guenter
    Whitney, J. Andrew
    Theurl, Igor
    BLOOD, 2017, 129 (13) : 1823 - 1830
  • [5] Nanocyclix® ALK2 Inhibitors to overcome cancer-induced anemia
    Benderitter, Pascal
    Caradec, Josselin
    Nicodeme, Edwige
    Bouillot, Anne
    Vaulont, Sophie
    Viollet, Benoit
    CANCER RESEARCH, 2020, 80 (16)
  • [6] The Jak1/Jak2 Inhibitor Momelotinib Inhibits Alk2, Decreases Hepcidin Production and Ameliorates Anemia of Chronic Disease (ACD) in Rodents
    Asshoff, Malte
    Warr, Matthew
    Haschka, David
    Tymoszuk, Piotr
    Petzer, Verena
    Demetz, Egon
    Maciejewski, Pat
    Seifert, Markus
    Nairz, Manfred
    Posch, Wilfried
    Fowles, Peter
    Weiss, Guenter
    Whitney, Andy
    Theurl, Igor
    BLOOD, 2015, 126 (23)
  • [7] Identification of novel ALK2 inhibitors and their effect on cancer cells
    Kim, Minsung
    Choi, Okran
    Pyo, Suhkneung
    Choi, Sang Un
    Park, Chi Hoon
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 492 (01) : 121 - 127
  • [8] A Monoclonal Antibody Targeting ALK2 As a Potential Therapeutic Agent for Anemia of Inflammation
    Medeiros, Natalia
    Backus, Thomas A.
    Mater, Christopher
    Fisher, Ffolliott
    Lachey, Jenn
    Seehra, Jasbir
    BLOOD, 2021, 138
  • [9] MICRORNA-130A DOWNREGULATES HEPCIDIN EXPRESSION DURING IRON DEFICIENCY BY TARGETING ALK2
    Zumbrennen-Bullough, Kimberly
    Wu, Qifang
    Chen, Wenjie
    Babitt, Jodie
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (05) : E9 - E9
  • [10] Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2
    Nguyen, Minh H.
    Atasoylu, Onur
    Wu, Liangxing
    Kapilashrami, Kanishk
    Pusey, Michelle
    Gallagher, Karen
    Lai, Cheng-Tsung
    Zhao, Peng
    Barbosa, Joseph
    Liu, Kai
    He, Chunhong
    Zhang, Colin
    Styduhar, Evan D.
    Witten, Michael R.
    Chen, Yaoyu
    Lin, Luping
    Yang, Yan-ou
    Covington, Maryanne
    Diamond, Sharon
    Yeleswaram, Swamy
    Yao, Wenqing
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, : 1159 - 1164
12345